At TNI BioTech, Inc. we have acquired a growing portfolio of patents related to both MENK and LDN, and are planning on clinical trials that will result in the commercialization of our patented technology. We are currently in negotiations to acquire a number of other immunotherapy products, patents and therapies and plan to start trials in the United States by early 2014, followed by clinical trials in China soon thereafter.
We expect to develop manufacturing capabilities for both LDN and MENK during 2013 for use in clinical trials.
We have a signed letter of intent to open oncology clinics in Africa that will provide for the treatment of cancer, HIV/AIDS and autoimmune diseases. Some of these clinics will be run with joint venture partners and others will be managed in connection with local hospitals. We understand the need for these treatment centers due to the explosion of advanced cancers in Africa where facilities for the diagnosis and treatment of cancer are minimal and there are almost no national cancer control programs. Cancer is now one of the leading causes of death in developing countries and already there are more deaths in the world from cancer than from AIDS, tuberculosis (TB) and malaria combined.
It is estimated that sub-Saharan Africa will see one million new cancer cases this year and it is predicted that the number of new cases will double in the next decade. The need to invest in new technology for the diagnosis and treatment exists and we at TNI BioTech, Inc. believe with the support of our partners and the individual governments, that the potential for success is very high.
We have been working with a Chinese Pharmaceutical Company for the last few months and expect to close on this transaction within the next few. This agreement will provide for additional trials in China. It is anticipated that this association will provide us with added revenues from licensing.